Compare PCRX & MAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | MAX |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 722.8M |
| IPO Year | 2011 | 2020 |
| Metric | PCRX | MAX |
|---|---|---|
| Price | $26.02 | $11.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $32.86 | $17.00 |
| AVG Volume (30 Days) | ★ 885.6K | 401.0K |
| Earning Date | 02-26-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | $716,791,000.00 | ★ $1,123,093,000.00 |
| Revenue This Year | $6.24 | $30.80 |
| Revenue Next Year | $9.53 | $8.49 |
| P/E Ratio | $55.17 | ★ N/A |
| Revenue Growth | 3.14 | ★ 64.86 |
| 52 Week Low | $18.18 | $7.33 |
| 52 Week High | $27.64 | $13.92 |
| Indicator | PCRX | MAX |
|---|---|---|
| Relative Strength Index (RSI) | 56.34 | 35.85 |
| Support Level | $24.20 | $11.37 |
| Resistance Level | $26.48 | $13.09 |
| Average True Range (ATR) | 0.98 | 0.41 |
| MACD | -0.12 | -0.16 |
| Stochastic Oscillator | 65.59 | 16.85 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.